Palmitate Impairs and Eicosapentaenoate Restores Insulin Secretion Through Regulation of SREBP-1c in Pancreatic Islets
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—Chronic exposure to fatty acids causes β-cell failure, often referred to as lipotoxicity. We investigated its mechanisms, focusing on contribution of SREBP-1c, a key transcription factor for lipogenesis. RESEARCH DESIGN AND METHODS—We studied in vitro and in vivo effects of saturated and polyunsaturated acids on insulin secretion, insulin signaling, and expression of genes involved in β-cell functions. Pancreatic islets isolated from C57BL/6 control and SREBP-1–null mice and adenoviral gene delivery or knockdown systems of related genes were used. RESULTS—Incubation of C57BL/6 islets with palmitate caused inhibition of both glucose- and potassium-stimulated insulin secretion, but addition of eicosapentaenoate (EPA) restored both inhibitions. Concomitantly, palmitate activated and EPA abolished both mRNA and nuclear protein of SREBP-1c, accompanied by reciprocal changes of SREBP-1c target genes such as insulin receptor substrate-2 (IRS-2) and granuphilin. These palmitate-EPA effects on insulin secretion were abolished in SREBP-1–null islets. Suppression of IRS-2/Akt pathway could be a part of the downstream mechanism for the SREBP-1c–mediated insulin secretion defect because adenoviral constitutively active Akt compensated it. Uncoupling protein-2 (UCP-2) also plays a crucial role in the palmitate inhibition of insulin secretion, as confirmed by knockdown experiments, but SREBP-1c contribution to UCP-2 regulation was partial. The palmitate-EPA regulation of insulin secretion was similarly observed in islets from C57BL/6 mice pretreated with dietary manipulations. Furthermore, administration of EPA to diabetic KK-Ay mice ameliorated impairment of insulin secretion in their islets. CONCLUSIONS—SREBP-1c plays a dominant role in palmitate-mediated insulin secretion defect, and EPA prevents it through SREBP-1c inhibition, implicating a therapeutic potential for treating diabetes related to lipotoxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Boden, G., & Shulman, G. I. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.32.s3.3.x · Cited by 1,300
Five stages of evolving beta-cell dysfunction during progression to diabetes
Weir, G. C., & Bonner-Weir, S. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s16 · Cited by 1,126 · cited 1×
“pancreatic islet β-cell failure, a crucial pathological contributor to the development for diabetes mellitus have been extensively explored (1-3).”
BackgroundLipotoxicity in the Pathogenesis of Obesity-Dependent NIDDM: Genetic and Clinical Implications
Unger, R. H. (1995) · Diabetes · doi:10.2337/diab.44.8.863 · Cited by 1,100
Insulin granule dynamics in pancreatic beta cells
Rorsman, P., & Renstr�m, E. (2003) · Diabetologia · doi:10.1007/s00125-003-1153-1 · Cited by 844
Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression
Sekiya, M., Yahagi, N., Matsuzaka, T., Najima, Y., Nakakuki, M., Nagai, R., Ishibashi, S., Osuga, J.-I., Yamada, N., & Shimano, H. (2003) · Hepatology · doi:10.1016/j.hep.2003.09.028 · Cited by 415 · cited 3×
“We previously reported that PUFAs inhibited hepatic SREBP-1c, which contributed to beneficial roles of PUFAs against lipotoxicity in the liver (22,23).”
BackgroundDysregulation of insulin receptor substrate 2 in β cells and brain causes obesity and diabetes
Lin, X., Taguchi, A., Park, S., Kushner, J. A., Li, F., Li, Y., & White, M. F. (2004) · Journal of Clinical Investigation · doi:10.1172/jci22217 · Cited by 313
Insulin receptor substrate 2 plays a crucial role in β cells and the hypothalamus
Kubota, N., Terauchi, Y., Tobe, K., Yano, W., Suzuki, R., Ueki, K., Takamoto, I., Satoh, H., Maki, T., Kubota, T., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21484 · Cited by 239
Free Fatty Acid-induced β-Cell Defects Are Dependent on Uncoupling Protein 2 Expression
Joseph, J. W., Koshkin, V., Saleh, M. C., Sivitz, W. I., Zhang, C.-Y., Lowell, B. B., Chan, C. B., & Wheeler, M. B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m409189200 · Cited by 206
Pancreatic β-Cell Protein Granuphilin Binds Rab3 and Munc-18 and Controls Exocytosis
Coppola, T., Frantz, C., Perret-Menoud, V., Gattesco, S., Hirling, H., & Regazzi, R. (2002) · Molecular Biology of the Cell · doi:10.1091/mbc.02-02-0025 · Cited by 127
Granuphilin Modulates the Exocytosis of Secretory Granules through Interaction with Syntaxin 1a
Torii, S., Zhao, S., Yi, Z., Takeuchi, T., & Izumi, T. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.15.5518-5526.2002 · Cited by 94 · cited 2×
“Granuphilin was an effector of Rab27a and its overexpression was reported to inhibit exocytosis of insulin granules (35-37).”
Background
Cited by
Wei, D., Li, J., Shen, M., Jia, W., Chen, N., Chen, T., Su, D., Tian, H., Zheng, S., Dai, Y., et al. (2010) · Diabetes · doi:10.2337/db09-0284 · Cited by 132
Lemaitre, R. N., Fretts, A. M., Sitlani, C. M., Biggs, M. L., Mukamal, K., King, I. B., Song, X., Djoussé, L., Siscovick, D. S., McKnight, B., et al. (2015) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.114.101857 · Cited by 117
Sawada, T., Tsubata, H., Hashimoto, N., Takabe, M., Miyata, T., Aoki, K., Yamashita, S., Oishi, S., Osue, T., Yokoi, K., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0437-y · Cited by 97
Zhang, D., Xie, T., & Leung, P. S. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000495395 · Cited by 65
Inhibition of microRNA-33b in humanized mice ameliorates nonalcoholic steatohepatitis
Miyagawa, S., Horie, T., Nishino, T., Koyama, S., Watanabe, T., Baba, O., Yamasaki, T., Sowa, N., Otani, C., Matsushita, K., et al. (2023) · Life Science Alliance · doi:10.26508/lsa.202301902 · Cited by 14
Metadata
- Authors
- Kato, T., Shimano, H., Yamamoto, T., Ishikawa, M., Kumadaki, S., Matsuzaka, T., Nakagawa, Y., Yahagi, N., Nakakuki, M., Hasty, A. H., Takeuchi, Y., Kobayashi, K., Takahashi, A., Yatoh, S., Suzuki, H., Sone, H., & Yamada, N.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2008-09-01
- Volume
- 57
- Issue
- 9
- Pages
- 2382-2392
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2117676499
- Cited by
- 102
- References
- 11
- FWCI
- 5.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.